Cargando…

Recent trends in antipsychotic polypharmacy in the treatment of schizophrenia

Ichihashi et al reported that 43% of patients had antipsychotic polypharmacy. Number of antipsychotics used in patients with schizophrenia in Japan was the greatest among Asian countries. However, the antipsychotic polypharmacy rate in Japan decreased gradually. Recent systematic review, meta‐analys...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yasui‐Furukori, Norio, Shimoda, Kazutaka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7722682/ https://www.ncbi.nlm.nih.gov/pubmed/32672006 http://dx.doi.org/10.1002/npr2.12127

Ejemplares similares

Effects of Antipsychotics on Arrhythmogenic Parameters in Schizophrenia Patients: Beyond Corrected QT Interval
por: Okayasu, Hiroaki, et al.
Publicado: (2021)

Cost of antipsychotic polypharmacy in the treatment of schizophrenia
por: Zhu, Baojin, et al.
Publicado: (2008)

Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
por: Faries, Douglas, et al.
Publicado: (2005)

Antipsychotic Polypharmacy in Treatment of Schizophrenia; Should or Should Not?
por: Pae, Chi-Un
Publicado: (2020)

Prescribing Trends for the Same Patients with Schizophrenia Over 20 Years
por: Yasui-Furukori, Norio, et al.
Publicado: (2023)

Hypoprolactinemia and hyperprolactinemia in male schizophrenia patients treated with aripiprazole and risperidone and their relationships with testosterone levels
por: Tasaki, Minami, et al.
Publicado: (2021)

Polypharmacy Management of Antipsychotics in Patients with Schizophrenia
por: Kamei, Hiroyuki
Publicado: (2022)

Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia
por: Bighelli, Irene, et al.
Publicado: (2022)

High-density lipoprotein-cholesterol and antipsychotic medication in overweight inpatients with schizophrenia: post-hoc analysis of a Japanese nationwide survey
por: Ono, Shin, et al.
Publicado: (2018)

Attitudes toward long-acting injectable antipsychotics among patients with schizophrenia in Japan
por: Sugawara, Norio, et al.
Publicado: (2019)

The effects of additional treatment with terguride, a partial dopamine agonist, on hyperprolactinemia induced by antipsychotics in schizophrenia patients: a preliminary study
por: Hashimoto, Kojiro, et al.
Publicado: (2014)

Hyperprolactinemia during antipsychotics treatment increases the level of coagulation markers
por: Ishioka, Masamichi, et al.
Publicado: (2015)

Projections of psychiatrists’ distribution for patients in Japan: a utilization-based approach
por: Sugawara, Norio, et al.
Publicado: (2021)

Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations
por: Lähteenvuo, Markku, et al.
Publicado: (2021)

Psychiatrists' Attitudes toward Metabolic Adverse Events in Patients with Schizophrenia
por: Sugawara, Norio, et al.
Publicado: (2014)

Relationship Between Cognitive Functions and Decision-Making Capacity in Older Institutionalized Patients with Schizophrenia: A Preliminary Study
por: Sugawara, Norio, et al.
Publicado: (2022)

Exploring Hidden Issues in the Use of Antipsychotic Polypharmacy in the Treatment of Schizophrenia
por: Kim, Jung-Jin, et al.
Publicado: (2021)

Treatment Discontinuation Among Patients with Schizophrenia Treated with Brexpiprazole and Other Oral Atypical Antipsychotics in Japan: A Retrospective Observational Study
por: Hishimoto, Akitoyo, et al.
Publicado: (2022)

A pregnant woman who experienced auditory hallucinations concurrent with hyperemesis gravidarum: A case report
por: Okayasu, Hiroaki, et al.
Publicado: (2021)

PM399. Attitudes toward antipsychotic long-acting injections among patients with Schizophrenia in Japan.
por: Kudo, Shuhei, et al.
Publicado: (2016)

Update on the development of lurasidone as a treatment for patients with acute schizophrenia
por: Yasui-Furukori, Norio
Publicado: (2012)

Factor structure of the University Personality Inventory in Japanese medical students
por: Sugawara, Norio, et al.
Publicado: (2020)

Attitudes of Medical Students toward COVID-19 Vaccination: Who Is Willing to Receive a Third Dose of the Vaccine?
por: Sugawara, Norio, et al.
Publicado: (2021)

Item response theory analysis of the University Personality Inventory in medical students
por: Sugawara, Norio, et al.
Publicado: (2023)

Antipsychotic Use Pattern in Schizophrenia Outpatients: Correlates of Polypharmacy
por: Yazici, Esra, et al.
Publicado: (2017)

Unresolved Issues for Utilization of Atypical Antipsychotics in Schizophrenia: Antipsychotic Polypharmacy and Metabolic Syndrome
por: Jeon, Sang Won, et al.
Publicado: (2017)

Schizophrenia, Depressive Symptoms, and Antipsychotic Drug Treatment
por: Reynolds, Gavin P, et al.
Publicado: (2021)

Antipsychotic Polypharmacy in Clozapine Resistant Schizophrenia: A Randomized Controlled Trial of Tapering Antipsychotic Co-treatment
por: Repo-Tiihonen, Eila, et al.
Publicado: (2012)

A case of musical hallucinations induced by tramadol
por: Hase, Tatsu, et al.
Publicado: (2023)

PM393. Antipsychotic polypharmacy patterns and antipsychotic psychiatric medication adherence in patients with schizophrenia
por: Joe, Soohyun, et al.
Publicado: (2016)

Antipsychotic patterns of use in patients with schizophrenia: polypharmacy versus monotherapy
por: Fisher, Maxine D, et al.
Publicado: (2014)

Working status of caregivers for people with dementia: Analysis data from a Japanese Nationwide Survey
por: Sugawara, Norio, et al.
Publicado: (2020)

Blood Levels of Ammonia and Carnitine in Patients Treated with Valproic Acid: A Meta-analysis
por: Yokoyama, Saaya, et al.
Publicado: (2022)

Survey of Health Literacy Among Japanese Outpatients with Mental Illness
por: Sato, Yoshiteru, et al.
Publicado: (2023)

Differences in etiological beliefs about schizophrenia among patients, family, and medical staff
por: Tarakita, Natsumi, et al.
Publicado: (2018)

High dose antipsychotic polypharmacy and dopamine partial agonists - time to rethink guidelines?
por: Reynolds, Gavin P
Publicado: (2021)

The More, the Merrier…? Antipsychotic Polypharmacy Treatment Strategies in Schizophrenia From a Pharmacology Perspective
por: Hjorth, Stephan
Publicado: (2021)

Consideration of Long-Acting Injectable Antipsychotics for Polypharmacy Regimen in the Treatment of Schizophrenia: Put It on the Table or Not?
por: Pae, Chi-Un, et al.
Publicado: (2021)

Prescription Patterns for Patients with Schizophrenia in Korea: A Focus on Antipsychotic Polypharmacy
por: Kim, Hee-Yun, et al.
Publicado: (2014)

Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: a review of systematic reviews
por: Ijaz, Sharea, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_tr8cedntllmitde219df75c5dv